Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study-Reference-Cited by-同舟云学术

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study

Published:2014-01 Issue:1 Volume:37 Page:1-8
ISSN:0210-5705
Container-title:Gastroenterología y Hepatología
language:en
Short-container-title:Gastroenterología y Hepatología

Author:

Fernández-Rodríguez Conrado M.,Morillas Rosa María,Masnou Helena,Navarro José María,Bárcena Rafael,González José Manuel,Martín-Martín Leticia,Poyato Antonio,Miquel-Planas Mireia,Jorquera Francisco,Casanovas Teresa,Salmerón Javier,Calleja José Luis,Solà Ricard,Alonso Sonia,Planas Ramón,Romero-Gomez Manuel

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin;Asselah;Liver Int,2010

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. Diagnosis, management, and treatment of hepatitis C: an update;Ghany;Hepatology,2009

4. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

5. Telaprevir for previously untreated chronic hepatitis C virus infection;Jacobson;N Engl J Med,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C genotype 3 disease;Hepatology International;2016-06-21

2. The ARRIBA concept: adequate resorption of ribavirin;Antiviral Therapy;2015